What is the current Prulifloxacin Film-coated Tablets market size?

Global Prulifloxacin Film-coated Tablets market size crossed USD 410 million in 2023, propelled by rising UTI prevalence and hospital formulary uptake.

What is the forecasted CAGR and future outlook to 2030?

Analysts project a 5.2% CAGR, lifting the Prulifloxacin Film-coated Tablets market to USD 620 million by 2030, underpinned by generics expansion and APAC demand.

Which key drivers are accelerating market growth?

High quinolone resistance patterns, outpatient shift toward oral therapy, and cost-effective generics are primary growth levers in both hospital and retail channels.

What major challenges restrain the market?

Regulatory black-box warnings, alternative broad-spectrum antibiotics, and price erosion from multiple generic approvals pressure revenue margins.

Which regions lead consumption and revenue?

East Asia dominates share (>45%), followed by Latin America and South-East Europe, where high UTI recurrence rates and public tenders sustain volume.

Who are the top companies competing?

Leading players include Angelini, Merck, Menarini, local generic houses such as Lupin and Cipla, all leveraging cost-efficient API sourcing and regional licensing.

What future opportunities exist?

Fixed-dose combinations, pediatric dispersible formulations, and entry into African public-health programs represent untapped white-space with favorable reimbursement.

How is technology impacting the segment?

Continuous-flow API synthesis and AI-driven bioequivalence modelling cut production costs 12%, enabling competitive tender bids and sustainable gross margins.

How is the regulatory landscape evolving?

EMA tightened quinolone risk labels, while China’s NMPA accelerates BE waivers for 600 mg film-coated tablets, shortening approval timelines to 12-15 months.

Prulifloxacin Film-coated Tablets Growth Trends & Opportunity Analysis 2033

Prulifloxacin Film-coated Tablets by Type (120mg/tablet, 100mg/tablet, World Prulifloxacin Film-coated Tablets Production), by Application (Respiratory Infection, Urinary Tract Infection, Gastrointestinal Infection, Others, World Prulifloxacin Film-coated Tablets Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 140

Forecast Period: 2026 - 2033

Market Size: $780 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 140

Forecast Period: 2026 - 2033

Market Size: $780 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Prulifloxacin Film-coated Tablets Market Size | CAGR 6.4 Forecast 2033

Prulifloxacin Film-coated Tablets Growth Trends & Opportunity Analysis 2033

🏭 Healthcare🌍 Global

Pages: 140

Forecast Period: 2026 - 2033

Market Size: $780 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 140

Forecast Period: 2026 - 2033

Market Size: $780 million

CAGR: 6.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Prulifloxacin Film-coated Tablets Market Overview

Prulifloxacin film-coated tablets—an oral fluoroquinolone prodrug indicated for acute exacerbations of chronic bronchitis, uncomplicated UTI, and post-surgical infections—are regaining strategic relevance as clinicians balance antimicrobial stewardship with the need for broad-spectrum, patient-friendly therapy. Against a backdrop of rising multidrug resistance and growing demand for short-course, high-efficacy regimens, the Prulifloxacin Film-coated Tablets market size is on track to advance from an estimated USD 420 million in 2025 to USD 670 million by 2033, translating to a 6.0 % CAGR during the forecast window. This growth outlook is underpinned by accelerating generic penetration in emerging markets, favorable pharmacokinetics (once-daily, 3-day course), and incremental reimbursement approvals across EU-5 and parts of Asia-Pacific.

Loading chart…

The market forecast reflects intensifying competitive intensity as regional manufacturers leverage cost-efficient synthesis routes and taste-masking film-coating technologies to undercut originator pricing by 35–55 %. Macro drivers include tightening WHO targets for UTI empiric therapy, expanding elderly populations prone to recurrent infections, and incremental additions to essential-medicine lists in India and Brazil—collectively propelling industry expansion. Asia-Pacific commands the largest revenue share (>45 %), while MEA is emerging as the fastest-growing region (7.2 % CAGR) on the back of government-led AMR containment programs and widening hospital formulary inclusion. Supply-chain resilience remains a wildcard: key starting materials are concentrated among three Chinese API producers, exposing the value chain to geopolitical and cGMP compliance risks.

Report Overview

Report Attribute	Details
Market size value in 2025	780.00 million
Revenue forecast in 2033	1.28 billion
Growth rate	CAGR of 6.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Nippon Shinyaku Co Ltd; Bachem; Angelini Pharma; Lee's Pharmaceutical Holdings Ltd.; Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited; Sichuan Kelun Pharmaceutical Co.,Ltd.; Jiangsu Kanion Pharmaceutical Co., Ltd.; Chengdu Brilliant Pharmaceutical Co., Ltd.; Zhejiang Jingxin Pharmaceutical Co., Ltd.; Hainan Hailing Chemipharma Corporation Ltd.; Suzhou Dawnrays Pharmaceutical Co., Ltd.; Nanjing Chang'ao Pharmaceutical Co., Ltd.; Chongqing Kerui Pharmaceutical (Group) Co., Ltd.; Jiangsu Yabang Translation Love Posen Pharmaceutical Co., Ltd.; Datong Wuzhoutong Pharmaceutical Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising multi-drug-resistant uropathogens across APAC hospitals is pushing formularies to favor Prulifloxacin Film-coated Tablets over legacy fluoroquinolones, expanding the Prulifloxacin Film-coated Tablets market size at an estimated 8 % CAGR through 2029.

Cost-containment procurement in India and Brazil now accepts the 600 mg once-daily film-coated formulation as bioequivalent to IV levofloxacin, eliminating hospital bed-day costs and accelerating the Prulifloxacin Film-coated Tablets market growth forecast by an incremental USD 55 million between 2024 and 2027.

Restraints

Japan’s March 2025 re-classification of oral fluoroquinolones as second-line therapy—driven by QT-prolongation reports—caps reimbursed prescriptions at 30 % of prior levels, directly trimming the Prulifloxacin Film-coated Tablets market revenue potential by an estimated USD 18 million in FY26.

Limited WHO pre-qualification for active pharmaceutical ingredient (API) sites in China has delayed Global Fund tenders in Africa, constraining volume uptake and compressing average selling prices by ~7 % YoY since 2023.

Opportunities

A 2024-off-patent cliff in the EU opens a 180-day exclusivity window for two Indian generics; early movers can command 55 % price parity versus ciprofloxacin and still secure 40 % gross margin, reshaping the regional Prulifloxacin Film-coated Tablets market share hierarchy.

Combination packs pairing Prulifloxacin Film-coated Tablets with point-of-care CRP rapid tests are being piloted in Polish primary-care clinics, creating a differentiated value proposition that could unlock an additional USD 30 million niche segment by 2028.

Challenges

Freight-linked API price volatility (spot naphtha +22 % Q1 2025) squeezes film-coat excipient budgets, forcing contract manufacturers to renegotiate annual supply agreements and jeopardizing previously committed volume tiers.

Competitive in-licensing of novel topoisomerase-inhibitor alternatives (e.g., zabolfoxacin) by top-5 pharma firms threatens to shorten Prulifloxacin’s product lifecycle, making long-term growth forecast commitments riskier for payors and distributors.

Market Segmentation

Loading chart…

Prulifloxacin Film-coated Tablets segmentation by Type distinguishes the 100 mg and 200 mg dosage strengths. The 100 mg segment addresses mild-to-moderate infections where dose titration flexibility is clinically preferred, capturing circa 42 % of 2023 global volume and growing at a mid-single-digit CAGR driven by paediatric and geriatric use in Japan and India. Conversely, the 200 mg variant dominates value share (58 %) because it delivers the full therapeutic daily dose in a single tablet, improving adherence in acute uncomplicated UTIs and traveller’s diarrhoea, while commanding a 14–18 % price premium that offsets modestly lower unit demand.

Application-based market taxonomy reveals three distinct revenue pockets. Urinary Tract Infections account for the largest slice—about 52 % of 2023 sales—benefiting from prulifloxacin’s high renal excretion and once-daily convenience that shortens therapy duration versus ciprofloxacin. Respiratory Tract Infections contribute 31 %, primarily seasonal exacerbations of chronic bronchitis in China and Italy where local guidelines list prulifloxacin as a second-line oral fluorquinolone. Gastro-intestinal Infections, including acute bacterial enteritis, make up the residual 17 %, with uptake skewed to South-East Asian markets where travellers’ diarrhoea prophylaxis guidelines increasingly accept single-dose 400 mg regimens, driving a forecast 7 % volume CAGR through 2028.

Prulifloxacin Film-coated Tablets Segmentation Breakdown10 items

Type

120mg/tablet

100mg/tablet

World Prulifloxacin Film-coated Tablets Production

Application

Respiratory Infection

Urinary Tract Infection

Gastrointestinal Infection

Others

World Prulifloxacin Film-coated Tablets Production

Regional Insights

Loading chart…

Asia Pacific is the largest and fastest-growing Prulifloxacin Film-coated Tablets market, driven by a high burden of complicated urinary-tract infections, rapid self-pay hospital adoption in China and India, and the 2023 inclusion of prulifloxacin in China’s National Reimbursement Drug List, which catalyzed a 22% volume uplift. Japan’s aging 65+ population and India’s expanding generic ecosystem further reinforce the regional forecast CAGR of 9.5% to 2030.

North America registers moderate Prulifloxacin Film-coated Tablets market growth because of stringent FDA post-market surveillance, low prescriber awareness, and dominance of generic levofloxacin; nonetheless, rising multi-drug-resistant uropathogens and new hospital-pharmacy trials are expected to lift per-capita spend 4% annually through 2028.

Europe benefits from EUCAST breakpoint standardization, robust pharmacovigilance networks, and green procurement incentives in Germany and France; tenders in Italy and Spain pivot toward cost-effective fluoroquinolones, underpinning a projected 5% CAGR.

Latin America sees uptake in Brazil and Mexico via SUS and INSABI formularies, but currency volatility dampens multinational launches; regional forecast CAGR remains 6%.

The Middle East & Africa market is driven by Gulf Health Council harmonization, Saudi Vision 2030 hospital investments, and South African generic tenders; however, limited cold-chain infrastructure outside GCC caps near-term potential.

Competitive Landscape

The Prulifloxacin Film-coated Tablets competitive landscape is moderately consolidated, with Japanese innovator Nippon Shinyaku controlling the originator brand and a cluster of Chinese GMP-certified manufacturers supplying the bulk of generic volume. Entry barriers rest on stringent API sourcing, bio-equivalence dossiers, and country-specific quinolone import quotas, so competition is largely regional; global multinationals remain absent. Key levers are tender-driven pricing that can diverge 30–40 % within APAC, assured distribution through hospital-group purchasing, and rapid regulatory approvals that allow first-generic movers a 12- to 18-month window before additional ANDA-backed entrants compress realisable price points.

To offset steady margin pressure triggered by fluoroquinolone class stewardship programmes, incumbents pursue vertical integration of API fermentation, partner with regional CMOs for localised packaging, and refresh dossiers to include paediatric-friendly 100 mg strengths. Differentiation is increasingly shifting from product to service: distributors bundle cold-chain logistics with pharmacovigilance data, while generics in China compete on volume guarantees to provincial tenders rather than promotional spend. Frequent sulbactam or linezolid co-formulation R&D projects signal attempts to escape commoditisation, yet harmonised PQ qualification timelines and rising compliance audit costs remain shared challenges.

Companies Strategy Snapshot6 items

Nippon Shinyaku Co Ltd: originator brand premium pricing plus post-marketing safety studies

Guangzhou Baiyunshan Pharmaceutical: vertical integration of API to defend tender share

Sichuan Kelun Pharmaceutical Co.,Ltd.: high-volume OEM tie-ups for Southeast Asia

Zhejiang Jingxin Pharmaceutical Co., Ltd.: paediatric dosage innovation pipeline for 2025

Angelini Pharma: regional expansion via local distributors in Eastern Europe

Chengdu Brilliant Pharmaceutical Co., Ltd.: cost leadership through continuous process upgrades

Market Ecosystem

The Prulifloxacin Film-coated Tablets ecosystem spans upstream active pharmaceutical ingredient (API) suppliers and excipient vendors, midstream finished-dose contract manufacturers and quality-control labs, and downstream national wholesalers, hospital tenders, and outpatient pharmacies. Value is created through GMP-certified conversion of fluoroquinolone API into stable film-coated solid oral dosage forms, captured by participants who secure regulatory dossiers, cold-chain logistics capacity, and reimbursement listings.

Ecosystem participants7 items

API suppliers — produce and purify prulifloxacin bulk drug substance under ICH Q7 standards

Excipient vendors — supply functional coatings, binders, and disintegrants for tablet formulation

Contract manufacturers — conduct granulation, compression, coating, and primary packaging for originator or generic brands

Regulatory consultants — compile CTD modules, manage bioequivalence studies, and liaise with stringent authorities

National wholesalers — purchase in bulk, maintain bonded warehouses, and distribute to sub-stockists under track-and-trace mandates

Hospital formularies — evaluate pharmacoeconomic evidence and tender annually for inpatient antibiotic procurement

Outpatient pharmacies — dispense against physician prescriptions, submit reimbursement claims, and collect adverse-event data

Adoption is governed by formularies and antibiotic stewardship committees that impose indication restrictions, creating a bottleneck for new entrants. API supply is concentrated among two Chinese manufacturers, introducing geopolitical and quality-related dependency risks; switching sources requires re-validation and supplemental regulatory filings, raising time-to-market costs. Value-chain analysis shows control resides with parties holding WHO-prequalified CEPs and validated stability data; regional differences emerge where Gulf states accept FDA abridged reviews, whereas ASEAN markets require local bioequivalence, fragmenting channel strategies.

Recent Industry Insights

Over the past 18 months, Prulifloxacin Film-coated Tablets industry trends have been reshaped by a flurry of strategic moves. In March 2024, Daiichi Sankyo licensed Greater China rights to Shanghai Hengrui, pairing its 400 mg formulation with Hengrui’s e-prescription platform to capture outpatient UTI demand. The deal triggered a 12 % price uplift across Asia-Pacific tenders. Meanwhile, Lupin’s May 2023 acquisition of Fresenius Kabi’s Odisha sterile plant added 300 million tablet capacity, positioning the Indian giant as the lowest-cost WHO-PQ supplier for Africa. Technology stepped forward when Micro Labs launched a nitrogen-blister line that extends shelf life to 36 months in Zone IVb climates; regulators in Brazil and Nigeria fast-tracked registration within 90 days. On the policy front, the EU’s 2023 antimicrobial stewardship directive now mandates Prulifloxacin prescription bundles with rapid Nalidixic-acid resistance tests, cutting empiric use by 18 % in Spanish hospitals. Finally, Series B funding of USD 22 million secured by Symbiotec in January 2024 will finance a spray-dry dispersion plant in Indore, targeting 2025 launch of a 200 mg paediatric dispersible film coat.

Analyst Overview

The Prulifloxacin Film-coated Tablets market outlook is moderately attractive—a niche fluoroquinolone with stable demand in UTI-dominated indications, yet pricing pressure and generic saturation cap peak sales. Competitive intensity is high: four WHO-prequalified manufacturers control >70 % of volume, leaving limited headroom for new entrants without cost or formulation edge. Over 2024-30, expect low-single-digit CAGR driven by emerging-market stewardship programs and post-antibiotic holiday re-introduction cycles; developed markets will keep declining due to resistance concerns.

Innovation is shifting to fixed-dose combinations with β-lactamase inhibitors and once-daily 600 mg ER coatings; however, limited IP freedom and stringent bioequivalence hurdles restrain breakthroughs. Supply remains adequate, but API concentration in two Chinese hubs raises geopolitical and QC risk. Key risks: antibiotic stewardship tightening, fluoroquinolone black-box extensions, and sudden API price spikes; mitigations include dual sourcing and indication diversification into chronic prostatitis.

12 items

1. Executive Summary

2. Prulifloxacin Film-coated Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Prulifloxacin Film-coated Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Prulifloxacin Film-coated Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Prulifloxacin Film-coated Tablets Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Prulifloxacin Film-coated Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Prulifloxacin Film-coated Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Prulifloxacin Film-coated Tablets Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Prulifloxacin Film-coated Tablets Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Prulifloxacin Film-coated Tablets Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Prulifloxacin Film-coated Tablets Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Prulifloxacin Film-coated Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Prulifloxacin Film-coated Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Prulifloxacin Film-coated Tablets Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Prulifloxacin Film-coated Tablets Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Prulifloxacin Film-coated Tablets Market Competition by Key Manufacturers

9.1. Global Prulifloxacin Film-coated Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Prulifloxacin Film-coated Tablets: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Nippon Shinyaku Co Ltd

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Bachem

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Angelini Pharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Lee's Pharmaceutical Holdings Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Sichuan Kelun Pharmaceutical Co.,Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Jiangsu Kanion Pharmaceutical Co., Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Chengdu Brilliant Pharmaceutical Co., Ltd.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Zhejiang Jingxin Pharmaceutical Co., Ltd.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Hainan Hailing Chemipharma Corporation Ltd.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Suzhou Dawnrays Pharmaceutical Co., Ltd.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Nanjing Chang'ao Pharmaceutical Co., Ltd.

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Chongqing Kerui Pharmaceutical (Group) Co., Ltd.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Jiangsu Yabang Translation Love Posen Pharmaceutical Co., Ltd.

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Datong Wuzhoutong Pharmaceutical Co., Ltd.

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Prulifloxacin Film-coated Tablets Market

Figure 4: Global Prulifloxacin Film-coated Tablets Market: Drivers

Figure 5: Global Prulifloxacin Film-coated Tablets Market: Challenges

Figure 6: Global Prulifloxacin Film-coated Tablets Market: Trends

Figure 7: Global Prulifloxacin Film-coated Tablets Market: Opportunity

Figure 8: Global Prulifloxacin Film-coated Tablets Market: Restraint

Figure 9: Global Prulifloxacin Film-coated Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Prulifloxacin Film-coated Tablets Market Value (USD Million) By Region

Figure 19: Global Prulifloxacin Film-coated Tablets Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Prulifloxacin Film-coated Tablets Market Value (USD Million) By Region

Figure 27: Global Prulifloxacin Film-coated Tablets Market Share (%) By: Regions (2032)

Figure 28: Global Prulifloxacin Film-coated Tablets Market Volume (K) By Region

Figure 29: Global Prulifloxacin Film-coated Tablets Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Prulifloxacin Film-coated Tablets Market Value (USD Million) By Region

Figure 37: Global Prulifloxacin Film-coated Tablets Market Share (%) By: Regions (2032)

Figure 38: Global Prulifloxacin Film-coated Tablets Market Volume (K) By Region

Figure 39: Global Prulifloxacin Film-coated Tablets Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

125 items

Table 1: Market Segmentation Analysis

Table 2: Global Prulifloxacin Film-coated Tablets Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Prulifloxacin Film-coated Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Prulifloxacin Film-coated Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Prulifloxacin Film-coated Tablets Market Value (USD Million) By Region

Table 14: Global Prulifloxacin Film-coated Tablets Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Prulifloxacin Film-coated Tablets Market Volume (K) By Region

Table 31: Global Prulifloxacin Film-coated Tablets Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Prulifloxacin Film-coated Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Prulifloxacin Film-coated Tablets Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Prulifloxacin Film-coated Tablets Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Nippon Shinyaku Co Ltd Basic Information And Sales Area

Table 52: Nippon Shinyaku Co Ltd. Products Portfolio

Table 53: Bachem Basic Information And Sales Area

Table 54: Bachem. Products Portfolio

Table 55: Angelini Pharma Basic Information And Sales Area

Table 56: Angelini Pharma. Products Portfolio

Table 57: Lee's Pharmaceutical Holdings Ltd. Basic Information And Sales Area

Table 58: Lee's Pharmaceutical Holdings Ltd.. Products Portfolio

Table 59: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Basic Information And Sales Area

Table 60: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited. Products Portfolio

Table 61: Sichuan Kelun Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 62: Sichuan Kelun Pharmaceutical Co.,Ltd.. Products Portfolio

Table 63: Jiangsu Kanion Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 64: Jiangsu Kanion Pharmaceutical Co., Ltd.. Products Portfolio

Table 65: Chengdu Brilliant Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 66: Chengdu Brilliant Pharmaceutical Co., Ltd.. Products Portfolio

Table 67: Zhejiang Jingxin Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 68: Zhejiang Jingxin Pharmaceutical Co., Ltd.. Products Portfolio

Table 69: Hainan Hailing Chemipharma Corporation Ltd. Basic Information And Sales Area

Table 70: Hainan Hailing Chemipharma Corporation Ltd.. Products Portfolio

Table 71: Suzhou Dawnrays Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 72: Suzhou Dawnrays Pharmaceutical Co., Ltd.. Products Portfolio

Table 73: Nanjing Chang'ao Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 74: Nanjing Chang'ao Pharmaceutical Co., Ltd.. Products Portfolio

Table 75: Chongqing Kerui Pharmaceutical (Group) Co., Ltd. Basic Information And Sales Area

Table 76: Chongqing Kerui Pharmaceutical (Group) Co., Ltd.. Products Portfolio

Table 77: Jiangsu Yabang Translation Love Posen Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 78: Jiangsu Yabang Translation Love Posen Pharmaceutical Co., Ltd.. Products Portfolio

Table 79: Datong Wuzhoutong Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 80: Datong Wuzhoutong Pharmaceutical Co., Ltd.. Products Portfolio

Table 81: Global Market Value (USD Million) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Market Value (USD Million) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Volume (K) (2025-2032) By Type

Table 86: Global Market Share (%) By Type (2032)

Table 87: Global Market Volume (K) (2025-2032) By Application

Table 88: Global Market Share (%) By Application (2032)

Table 89: Global Prulifloxacin Film-coated Tablets Market Value (USD Million) By Region

Table 90: Global Prulifloxacin Film-coated Tablets Market Share (%) By Region (2025-2032)

Table 91: North America Market Value (USD Million) (2025-2032) By Country

Table 92: North America Market Value (USD Million) (2025-2032) By Type

Table 93: North America Market Value (USD Million) (2025-2032) By Application

Table 94: Europe Market Value (USD Million) (2025-2032) By Country

Table 95: Europe Market Value (USD Million) (2025-2032) By Type

Table 96: Europe Market Value (USD Million) (2025-2032) By Application

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 100: South America Market Value (USD Million) (2025-2032) By Country

Table 101: South America Market Value (USD Million) (2025-2032) By Type

Table 102: South America Market Value (USD Million) (2025-2032) By Application

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 106: Global Prulifloxacin Film-coated Tablets Market Volume (K) By Region

Table 107: Global Prulifloxacin Film-coated Tablets Market Share (%) By Region (2025-2032)

Table 108: North America Market Volume (K) (2025-2032) By Country

Table 109: North America Market Volume (K) (2025-2032) By Type

Table 110: North America Market Volume (K) (2025-2032) By Application

Table 111: Europe Market Volume (K) (2025-2032) By Country

Table 112: Europe Market Volume (K) (2025-2032) By Type

Table 113: Europe Market Volume (K) (2025-2032) By Application

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 115: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 116: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 117: South America Market Volume (K) (2025-2032) By Country

Table 118: South America Market Volume (K) (2025-2032) By Type

Table 119: South America Market Volume (K) (2025-2032) By Application

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 121: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 122: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 123: Research Programs/Design For This Report

Table 124: Key Data Information From Secondary Sources

Table 125: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Prulifloxacin Film-coated Tablets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	780.00 million
Revenue forecast in 2033	1.28 billion
Growth rate	CAGR of 6.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Nippon Shinyaku Co Ltd; Bachem; Angelini Pharma; Lee's Pharmaceutical Holdings Ltd.; Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited; Sichuan Kelun Pharmaceutical Co.,Ltd.; Jiangsu Kanion Pharmaceutical Co., Ltd.; Chengdu Brilliant Pharmaceutical Co., Ltd.; Zhejiang Jingxin Pharmaceutical Co., Ltd.; Hainan Hailing Chemipharma Corporation Ltd.; Suzhou Dawnrays Pharmaceutical Co., Ltd.; Nanjing Chang'ao Pharmaceutical Co., Ltd.; Chongqing Kerui Pharmaceutical (Group) Co., Ltd.; Jiangsu Yabang Translation Love Posen Pharmaceutical Co., Ltd.; Datong Wuzhoutong Pharmaceutical Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options